Restoring XIAP function to treat inflammatory bowel disease
Modulating XIAP for the Treatment of Inflammatory Bowel Disease
This study is looking at how to help people with inflammatory bowel disease (IBD) by boosting a protein called XIAP that helps keep the intestines healthy, with the hope of reducing inflammation and improving symptoms.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10915575 on NIH RePORTER |
What this research studies
This research focuses on inflammatory bowel disease (IBD), a chronic condition affecting the intestines. It aims to address the underlying cause of IBD by restoring the activity of a protein called XIAP, which is crucial for preventing excessive cell death in the intestinal lining. By targeting XIAP, the research seeks to reduce inflammation and improve the health of the intestinal barrier, potentially leading to better management of IBD symptoms. The approach involves manipulating specific proteins that regulate XIAP to enhance its function.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with inflammatory bowel disease who have not responded adequately to current treatments.
Not a fit: Patients with IBD who have already achieved remission or those with other gastrointestinal disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that not only alleviates symptoms of IBD but also addresses its root causes.
How similar studies have performed: While targeting XIAP is a novel approach, previous research has shown promise in manipulating apoptosis pathways for treating inflammatory conditions.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Blander, Julie Magarian — Weill Medical Coll of Cornell Univ
- Study coordinator: Blander, Julie Magarian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.